{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-127487","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2024-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.954489+00:00","generated_at":"2026-05-29T04:37:56.291591+00:00","sec_items":["2.05","8.01","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cellectar pivots away from iopofosine I 131 accelerated approval; cuts workforce 60%","bullets":["Due to FDA Type-C meeting, accelerated approval for iopofosine I 131 would now require randomized confirmatory study with PFS endpoint; company seeking strategic options for this program.","Workforce cut ~60%; expects annual operating cost savings of ~$7.5M and ~$1.7M severance costs in Q4 2024/Q1 2025.","Shifting focus to alpha- (CLR 121225) and Auger-emitter (CLR 121125) programs; expects to file IND applications in H1 2025 for Phase 1 solid tumor studies.","Restructuring expected to extend cash runway into Q3 2025 from earlier depletion estimate."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-127487","json":"https://secwatch.observer/filing/0001104659-24-127487.json","markdown":"https://secwatch.observer/filing/0001104659-24-127487.md","text":"https://secwatch.observer/filing/0001104659-24-127487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924127487/0001104659-24-127487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924127487/tm2430732d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:37:56.291591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b823573a56d8fa3a8196c5cc864844c893f58f0","claim":"Cellectar Biosciences, Inc. announced a restructuring with charges of approximately $1.7 million affecting overall workforce (approximately 60%).","evidence_excerpt":"will decrease its annual operating costs by approximately $7.5 million. Additionally, the Company estimates that it will incur aggregate severance costs of approximately $1.7 million, which will be recorded primarily in the fourth quarter of 2024 and first quarter of 2025. The cost that the Company expects to incur in connection with the workforce reduction","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465924127487/0001104659-24-127487-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.7 million"},{"label":"Affected area","value":"overall workforce"},{"label":"Headcount","value":"approximately 60%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}